our target diseases industrial recognitionopertechnology.com/download/leaflet_english.pdf ·...
TRANSCRIPT
Neural to Neural
Self to Self
Innova&ng(for(Incurable(Diseases(
Autologous Neural Stem Cell Harvest Technology (US & HK Patented)
CONTACT Address: Unit 517, 5/F Biotech Centre 2, No.11 Science Park West Avenue Hong Kong Science Park, Shatin, N.T., Hong Kong Email: [email protected] Tel: +852 2336 7900 Fax: +852 2336 7099 For more information:
http://opertechnology.com
Our Target Diseases
Visit%our%Website% Like%us%on%Facebook%
Parkinson’s Disease (PD)
Alzheimer’s Disease (AD)
Huntington’s Disease (HD)
Strokes Spinal Cord Injuries (SCI)
�Multiple Sclerosis ��(MS)
Neurodegenerative Diseases
Cancer Metastatic cancer
http://opertechnology.com
Industrial Recognition Incurable diseases%
Revolutionize current symptom-relief treatments
Minimize undesirable side-effects of current treatments
OPER( Technology( Limited((is% dedicated% to% provoking% revolu7onary% changes% in%the% prac7ce% of% PRECISION% MEDICINE% and%REGENERATIVE% MEDICINE,% and% bringing% a% new%possibility% in% the% new% era% of% therapeu7cs% that%focuses%on%PERSONALIZED%and%PRECISION%MEDICINE%
Neurodegenerative Disease Population
(Including*only*AD,*PD,*HD,*MS,*SCI*and*Strokes)*
US >18.46M Patients
China >23.5M Patients
World: Over 100M Patients
HUGE BUT UNMET MARKET
Cost & Investments
for worldwide medical and economic cost on neurodegenerative diseases
Research Platform Clinical Platform WHY TRUST IN OPER A N S c H A R V E S T ?
• Pioneering(the(use(of(ANScs(for(research(and(clinical(purposes(in(the(world%We*are*the*FIRST*and*ONLY*group*in*the*world*successfully*extracIng*acIve*adult*NScs*from*live*subject*without*the*sacrifice*of*life*
• Innova&ve(nanomaterialCbased(technology(• US(and(HK(patented(• CostCefficient(• Minimally(invasive(• Low(tendency(in(tumour(forma&on(• No(use(of(virus(• No(gene&c(engineering(• Safe(
Funding used across the National Institute of Health, 10/02/2016
Autologous Neural Stem Cell (ANSc) Harvest
Promising Cure for Neurodegenerative Diseases
High investment potential
Around USD$1000B per year
Providing ANScs for research and medical institutes and pharmaceutical companies
Serving ANScs Harvest as a treatment targeting neurodegenerative diseases
Drug Discovery & development
Validation &
Verification
Researches with primary neural stem
cells
same animal
same cell source
Higher Accuracy & Cons i s tency
Patient
1. ANSc Harvest
2a. Autologous cell replacement therapy
Stem Cell Bank
2b. Storage
Genotyping